June 2017 Volume 13, Issue 6

Volume 13, Issue 6 | June 2017
June 2017
In this Issue
Preclinical

In pursuit of pertussis prevention
Preclinical study shows SYN-005 offers protection from whooping cough
Galapagos presents GLPG1972 data at OARSI meeting
Compound is a potent, selective, orally available ADAMTS-5 inhibitor for osteoarthritis
Platelet partnership
Plasticell taps Kings College London for preclinical studies of its blood platelet substitute
Triple scoop of early-stage data
Immunovaccine, Idera and Sunesis all share preclinical research results at AACR 2017Business & Government Policy

A couple more indications for CB-839
Bristol-Myers Squibb and Calithera expand cancer deal into NSCLC and melanoma
Ireland makes strong push to host EMA
Nation cites case for continuity as European Medicines Agency prepares to leave United Kingdom
On the cutting edge
A roundup of instrumentation, software and other tools and technology news
Boehringer Ingelheim strengthens early science portfolio
Long-term collaboration partnership with Peking University to harness new scientific discoveries in areas of high unmet medical needClinical Trials

Brings a tear to your eye
Shire and Parion Sciences sign off on license agreement to advance P-321 for dry eye disease
Down with the resistance
SCY-078 proves effective against multidrug-resistant fungus
Centralization in clinical trials
ASCO and NCI partner to explore the potential of centralized coverage analysis
Bioequivalent patch for Alzheimer’s
Corium reports positive preliminary results for alternate formulation of donepezil
Head and neck ahead
Trial combines Regeneron’s PD-1 inhibitor and Inovio’s T cell and immune activators in glioblastoma multiformeSpecial Reports

Special Report on Cancer Metabolomics: Into the metabolic maelstrom
Metabolomics shifts from map-making to therapeutic strategizingFeature

Post-show wrap-up: Digging deep into IO at AACR
Earlier-stage cancer programs remain a mainstay of American Association for Cancer Research (AACR) annual meeting generally, but immuno-oncology approaches stand outDiscovery

New progress with PAR2
Collaborative work from Heptares and AstraZeneca reveals X-ray crystal structures of a GPCR of interest
New answers on muscle regeneration
Research explaining why aged muscle loses ability to regenerate comes with caution
Abeome and CDC collaborate on Zika antibody
The deal will leverage Abeome's AbeoMouse platform to generate novel monoclonal antibodies
Moving along with methyltransferase inhibitors
Epizyme earns $10- million milestone payment from GSK under inhibitor dealEditor's Focus

History in the making
FDA’s approval of Merck & Co.’s pembrolizumab marks a watershed moment, heralding the possible era of 'tumor-agnostic' drug approvalsResearch & Development

A new agreement for old partners
InSphero and Pfizer to jointly develop predictive liver toxicology measurement tool
TSRI tests new drug-making methods
Chemists devise simple method for making sought-after boronic acid-based drugs and other products
Early immunotherapy
Barcoding maps immune system components before cancer progresses
Gyros Protein and Luxembourg Bio sign distribution agreement
Deal for peptide synthesis reagents includes exclusive distribution of PurePep coupling agents in North AmericaContract Services

Two for the top three
INC and inVentiv sign merger agreement; combined company would be one of the top three CROs
Immuno-oncology growing on Horizon
Current and ongoing sales and service projects in IO realm represent nearly 40-percent increase
CRO on the move
PPD combines units, creates apprenticeship, adds personnelDiagnostics

A weapon against antibiotic resistance
U.S. Department of Defense funds effort to create tool for differentiating bacterial infections from viral ones
Using IL-1 genotypes to predict cardiovascular events
Findings of study by Interleukin Genetics enhance the understanding of the role of genetics in cardiovascular disease
A new option in NIPT
Hamilton Robotics and Illumina collaborate on automated, next-gen workflow for prenatal testing
‘Scent of a cancer’
Hitachi and Hirotsu Bio Science round up roundworms to sniff out cancerCommentary

Bubbles that need some popping
Scientific papers and presentations are good, but have we reached the point there are so many journals and so many conferences that we are losing serious ground with regard to how many of them are reputable, valuable and/or to be trusted?

Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe